Urologix®, Inc. (NASDAQ: ULGX), a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting’s sub-specialty society, the Geriatric Urological Society (GUS) meeting, to be held at the Marriot Nob Hill in San Francisco on Sunday, May 30, 2010 from 3:00pm to 5:00pm PDT. “We are pleased the Geriatric Urological Society selected ‘Sexual Function after Cooled High Energy Transurethral Thermotherapy: Results of Patient Clinical Data up to 5 Years Post-Treatment’ and ‘Intra-Prostatic Temperatures and Necrosis during High Energy Cooled Microwave Treatment’ for presentation,” said Stryker Warren jr., Chief Executive Officer. “Urologix has led the minimally invasive space for the treatment of BPH when one inventories the clinical studies and the resultant publications and presentations. This speaks to both the efficacy of our technology and our commitment to the science of high energy, cooled microwave therapy. We are gratified by the interest again this year in clinical abstracts which advance the knowledge and the comparative effectiveness of high energy, Cooled ThermoTherapy™ which is the province of Urologix.” Thayne Larson, MD will present the two abstracts in a podium session. Dr. Larson is one of the early participants in clinical trials with Urologix in 1991; he practiced at the Mayo Clinic, Scottsdale, AZ and now is an independent researcher at The Institute of Medical Research, Scottsdale, AZ. Urologix is an exhibitor at the AUA 2010 Annual Meeting at the Moscone Center in San Francisco from May 29 through June 1, 2010. The exhibit will emphasize the advantages of Cooled ThermoTherapy™ versus BPH drugs while also demonstrating the distinct difference in peer reviewed published data available to support cooled high-energy transurethral microwave therapy versus low energy alternatives.